How to cite item

Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?

   
@article{TAU24487,
	author = {Moritz Maas and Arnulf Stenzl},
	title = {Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?},
	journal = {Translational Andrology and Urology},
	volume = {8},
	number = {Suppl 3},
	year = {2019},
	keywords = {},
	abstract = {The use of cisplatin-based neoadjuvant chemotherapy (NAC) for all patients with muscle-invasive bladder cancer (MIBC) is recommended by current guidelines (1,2). However, the study of Bhindi et al. suggest, that patients not responding to NAC show an inferior survival than a comparable control group (3). Furthermore, only 20–38% of the patients exposed towards NAC show a histopathological response (4). Taking these aspects and the known chemotherapy-related toxicity into consideration leads both, providers and patients, to the question whether the potential benefits of NAC outweigh its disadvantages.},
	issn = {2223-4691},	url = {https://tau.amegroups.org/article/view/24487}
}